Advertisement

Osteoporosis International

, Volume 3, Supplement 1, pp 218–222 | Cite as

Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate

  • A. G. Need
  • B. E. C. Nordin
  • B. E. Chatterton
Session XI: Treatment: Fluoride, Bisphosphonates, Anabolic Steroids And New Developments

Keywords

Public Health Osteoporosis Decanoate Nandrolone Nandrolone Decanoate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chestnut CH, Nelp WB, Baylink DJ, Denney JD. Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass. Metabolism 1977;26:267–77.Google Scholar
  2. 2.
    Dequeker J, Geusens P. Anabolic steroids and osteoporosis. Acta Endocrinol 1985;271:S45-S52.Google Scholar
  3. 3.
    Need AG, Nordin BEC. Eight years experience with nandrolone decanoate therapy. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen:Osteopress, 1990:2034–9.Google Scholar

Copyright information

© European Foundation for Osteoporosis 1993

Authors and Affiliations

  • A. G. Need
    • 1
  • B. E. C. Nordin
    • 1
  • B. E. Chatterton
    • 2
  1. 1.Institute of Medical and Veterinary ScienceDivision of Clinical ChemistryAdelaideSouth Australia
  2. 2.Department of Nuclear MedicineRoyal Adelaide HospitalAdelaideSouth Australia

Personalised recommendations